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Abstract A highly aggressive subset of pancreatic ductal adenocarcinomas undergo trans-
differentiation into the squamous lineage during disease progression. Here, we investigated
whether squamous trans-differentiation of human and mouse pancreatic cancer cells can influence
the phenotype of non-neoplastic cells in the tumor microenvironment. Conditioned media
experiments revealed that squamous pancreatic cancer cells secrete factors that recruit neutrophils
and convert pancreatic stellate cells into cancer-associated fibroblasts (CAFs) that express
inflammatory cytokines at high levels. We use gain- and loss-of-function approaches to show that
squamous-subtype pancreatic tumor models become enriched with neutrophils and inflammatory
CAFs in a p63-dependent manner. These effects occur, at least in part, through p63-mediated
activation of enhancers at pro-inflammatory cytokine loci, which includes IL1A and CXCL1 as key
targets. Taken together, our findings reveal enhanced tissue inflammation as a consequence of
squamous trans-differentiation in pancreatic cancer, thus highlighting an instructive role of tumor
cell lineage in reprogramming the stromal microenvironment.
Introduction
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human tumors, with a five year
survival rate below 10% (Siegel et al., 2020). Despite the overall association with poor clinical out-
comes, a striking heterogeneity in the presentation and progression of this disease exists between
individuals, including differing rates of metastatic spread and responses to cytotoxic chemotherapy
(Collisson et al., 2019). Owing to this issue, a major objective in PDA research is to uncover molecu-
lar mechanisms that underpin this clinical heterogeneity. Such efforts may yield much-needed bio-
markers capable of predicting disease progression, as well as personalized therapeutic strategies
that target critical disease drivers in each patient’s tumor.
It has long been recognized that a subset of pancreatic tumors exhibit an ‘adenosquamous’ his-
tology, which is characterized by the presence of both glandular and squamous neoplastic cells
within the same tumor (Ishikawa et al., 1980; Morohoshi et al., 1983; Motojima et al., 1992). The
designation of adenosquamous pancreatic cancer as a disease entity has been reinforced by several
recent transcriptome profiling studies of human pancreatic tumors, which identified aberrant
Somerville et al. eLife 2020;9:e53381. DOI: https://doi.org/10.7554/eLife.53381 1 of 30
RESEARCH ARTICLE
expression of squamous (also known as basal) lineage markers in ~15% of samples, in association
with exceptionally poor clinical outcomes (Bailey et al., 2016; Cancer Genome Atlas Research Net-
work, 2017; Moffitt et al., 2015). While squamous cells are a normal cell type in several stratified
epithelial tissues (e.g. in the skin and esophagus), they are not known to be present in the normal
human pancreas (Basturk et al., 2005). This suggests an aberrant ductal-to-squamous epithelial cell
fate transition is induced during pancreatic tumorigenesis.
The functional relevance of squamous trans-differentiation in pancreatic cancer was unclear until
recently, when studies from several laboratories, including our own, demonstrated that the transcrip-
tion factor p63 (DN isoform, hereafter referred to as p63 for simplicity) is the master regulator of the
adenosquamous phenotype in PDA (Andricovich et al., 2018; Hamdan and Johnsen, 2018;
Somerville et al., 2018). The p63 protein is encoded by the TP63 gene in humans. Once expressed,
p63 binds to thousands of genomic sites to nucleate the formation of active enhancers to drive
expression of squamous lineage genes (e.g. KRT5/6 and S100A2) in PDA cells (Hamdan and John-
sen, 2018; Somerville et al., 2018). Importantly, p63 is both necessary and sufficient to endow PDA
cells with the same squamous lineage transcriptional program that is observed in pancreatic tumors
with adenosquamous histology (Bailey et al., 2016; Hamdan and Johnsen, 2018; Somerville et al.,
2018). While the mechanisms that induce p63 expression in PDA remain unclear, it has been shown
in mice that inactivation of the tumor suppressor Kdm6a or over-expression of Myc can predispose
pancreatic tumors to express squamous markers, albeit with partial penetrance (Andricovich et al.,
2018; Hayashi et al., 2020; Witkiewicz et al., 2015). In support of the functional impact of squa-
mous trans-differentiation in PDA, induction of p63 leads to a collection of cell-autonomous pheno-
typic alterations, including enhanced motility, invasion, and resistance to cytotoxic chemotherapy
(Danilov et al., 2011; Somerville et al., 2018).
Evidence from human patients and mouse models supports a powerful effect of inflammation in
driving PDA progression (Cobo et al., 2018; Guerra et al., 2011; Guerra et al., 2007; Yadav and
Lowenfels, 2013). A key step in this process is an elaboration of pro-inflammatory cytokines by
tumor cells and non-neoplastic cells in the stromal compartment (Mantovani et al., 2008). For
example, many pancreatic tumors are infiltrated with neutrophils, which suppress anti-tumor T-cell
immunity in PDA mouse models and correlate with aggressive disease in humans (Bayne et al.,
2012; Chao et al., 2016; Inoue et al., 2015; Shen et al., 2014; Steele et al., 2016). A major cell
type in the stroma of PDA tumors are CAFs, which have historically been considered tumor-promot-
ing (O¨hlund et al., 2014), however recent studies suggest they may also have tumor-restraining
functions (O¨zdemir et al., 2014; Rhim et al., 2014). A subset of CAFs with myofibroblastic proper-
ties, termed myCAFs, appear to be involved in the production of extracellular matrix which may limit
drug delivery to the tumor (Olive et al., 2009; Provenzano et al., 2012; Sherman et al., 2014).
Another subset of CAFs, termed iCAFs, have low expression of myCAF markers and instead produce
high levels of inflammatory cytokines and chemokines, such as IL-6, CXCL1, and LIF (O¨hlund et al.,
2017). Although the iCAF/myCAF ratio, the extent of neutrophil infiltration, and the overall level of
stromal inflammation can vary between PDA patients, the underlying features of cancer cells that
drive these differences are only beginning to be understood (Biffi et al., 2019; Steins et al., 2020;
Vennin et al., 2019).
Here we provide evidence that p63-expressing squamous PDA cells have an enhanced capability
to promote inflammatory changes within the tumor microenvironment when compared to p63-nega-
tive PDA cells. These findings are supported by in vitro and in vivo experiments, and include activa-
tion of an inflammatory transcriptional program in CAFs of the tumor stroma. These effects are
mediated via a specific cytokine secretion phenotype of PDA cells downstream of p63-mediated
enhancer reprogramming. Taken together, these findings illustrate how lineage alterations within
cancer cells orchestrate non cell-autonomous changes in the tumor microenvironment.
Results
A secretory phenotype of p63-positive PDA cells that promotes
inflammatory gene expression changes in CAFs in vitro
In a prior study, we found that ectopic expression of p63 in the human PDA cell line SUIT2, which
lacks endogenous p63 expression, enhanced cell growth when implanted into the mouse pancreas
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in vivo, yet this phenotype was absent under tissue culture conditions (Somerville et al., 2018).
These findings led us to hypothesize that p63 expression alters how PDA cells communicate with
non-neoplastic cells in the tumor stroma. We focused our studies initially on CAFs, which have estab-
lished roles in PDA pathogenesis (Pereira et al., 2019). To this end, we collected conditioned media
from 12 human PDA cell lines exhibiting different expression levels of squamous markers (e.g. TP63
and KRT5) (Figure 1A–C and Figure 1—figure supplement 1A). Of note, MIAPaca2 cells only
express the TA isoform of p63 (Figure 1—figure supplement 1A) and lack expression of squamous
lineage markers (Somerville et al., 2018), and in fact are more representative of a cell type of neuro-
endocrine origin (Yu et al., 2019). The collected media were then applied to quiescent murine pan-
creatic stellate cells (PSCs), which are a precursor of CAFs in PDA, and RNA-sequencing (RNA-seq)
analysis was performed on the PSC cultures following 96 hr to evaluate the cellular response
(Figure 1D). An unsupervised clustering of the global transcriptional profile of the PSCs revealed
three distinct groups (Figure 1E). Two of the treated PSC cultures clustered closely with the
untreated controls, suggesting they remained in a quiescent transcriptional state (Figure 1E). How-
ever, two major groups were found to cluster away from the control PSC cultures and were termed
Group 1 and Group 2 (Figure 1E). Remarkably, the PSCs within the Group 2 cluster were all treated
with conditioned media derived from the three PDA cell lines expressing p63 (BxPC3, T3M4, and
KLM1; Figure 1A–B and Figure 1—figure supplement 1A). In addition to this transcriptional pheno-
type, the conditioned media from p63-expressing lines also led to a stronger induction of PSC prolif-
eration than conditioned media collected from p63-negative lines (Figure 1—figure supplement
1B–C). We next extracted the subset of genes that discriminate the Group 1 and Group 2 clusters of
PSC transcriptional responses, identifying 144 and 259 differentially expressed genes, respectively
(Figure 1F and Supplementary file 1). A Gene Set Enrichment Analysis (GSEA) of the Group 2 clus-
ter revealed several top-ranking gene signatures associated with inflammation (Figure 1G and Fig-
ure 1—figure supplement 1D). Using transcriptome data from our prior study in which we
identified iCAFs and myCAFs (O¨hlund et al., 2017), we defined gene signatures associated with
these two cell fates (Supplementary file 2) and observed a significant enrichment of the iCAF signa-
ture within the Group 2 set of PSCs (Figure 1H). In contrast, the myCAF signature was significantly
enriched within Group 1 PSCs (Figure 1I). RT-qPCR analysis of human PSCs treated with conditioned
media from PDA cell lines further validated these findings (Figure 1—figure supplement 1E). These
findings suggested that a pro-inflammatory secretory phenotype is linked with the acquisition of
squamous features in PDA.
p63 expression in PDA cells drives a secretory phenotype that induces
iCAF formation in vitro
Based on the correlations described above, we next set out to determine the causality between p63
and the iCAF-inducing secretory phenotype. To this end, we cultured two mouse PSC lines with con-
ditioned media harvested from SUIT2-empty and SUIT2-p63 cells and performed RT-qPCR analysis
of iCAF marker genes in the PSC cultures (Figure 2A). We observed a marked increase in iCAF
markers (Il6, Cxcl1, and Lif) and a concomitant reduction of myCAF markers (Acta2 and Ctgf) when
the PSCs were cultured in the SUIT2-p63 conditioned media compared to those cultured in SUIT2-
empty conditioned media (Figure 2B–C and Figure 2—figure supplement 1A–B). In accord with
the findings described above, mouse PSCs cultured in the SUIT2-p63 conditioned media were more
proliferative when compared to their counterparts cultured in SUIT2-empty conditioned media (Fig-
ure 2—figure supplement 1C–D). Similar RT-qPCR experiments using human PSC cultures or using
a metastatic mM1 organoid line, which was isolated from the KPC (Kras+/LSL-G12D; Trp53+/LSL-R172H;
Pdx1-Cre) mouse model (Boj et al., 2015; Hingorani et al., 2005), and engineered to ectopically
express p63, support the generality of these findings (Figure 2D–E and Figure 2—figure supple-
ment 1E–F).
We next performed loss-of-function studies using conditioned media from KLM1-Cas9 cells
infected with two independent sgRNAs targeting TP63 or a control sgRNA (Figure 2F). Notably,
KLM1 is the only p63-positive PDA cell line we have identified which does not exhibit a growth arrest
phenotype in vitro following p63 inactivation (Figure 2—figure supplement 1G–
H; Somerville et al., 2018). Importantly, KLM1 cells harbor a similar transcriptional and epigenomic
profile as observed in other p63-expressing PDA cell lines (Figure 2—figure supplement 1I–K). In
addition, KLM1 cells also induce a similar iCAF phenotype as seen with other p63-expressing lines
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(Figure 1E–F). Hence, this cell line is useful for performing p63 loss-of-function experiments evaluat-
ing for secretory phenotypes without the confounding effect of impairing cell fitness.
While conditioned media from KLM1 cells led to a significant induction of iCAF markers and
repression of myCAF markers in mouse and human PSCs, this effect was significantly attenuated in
p63-knockout KLM1 cells (Figure 2G–I and Figure 2—figure supplement 1L–N). In addition, the
proliferation phenotype of the conditioned media-treated PSCs was also attenuated following p63
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Figure 1. A secretory phenotype of p63-positive PDA cells that promotes inflammatory gene expression changes in CAFs in vitro. (A) Western blot
analysis showing p63 expression in a panel of 12 human PDA cell lines. (B–C) Bar charts show expression of TP63 and KRT5 cell lines shown in (A). (D)
Schematic of experimental workflow for RNA-seq analysis of PSCs following culture in Matrigel with conditioned media from the 12 human PDA cell
lines. (E) Heatmap representation of unsupervised hierarchical clustering of mouse PSCs based on their global transcriptional profile. Scale bar
indicates Pearson correlation coefficient. Control refers to control media, which was DMEM supplemented with 5% FBS. (F) Heatmap representation of
differentially expressed genes from PSCs in Group 1 and Group 2. Selected genes in each group are listed. Scale bar indicates standardized expression
value. (G) GSEA plot evaluating Hallmark Inflammatory Response genes based on their expression in Group 2 versus Group 1 cultures. (H–I) GSEA plots
evaluating the iCAF and myCAF gene signatures in Group 2 versus Group 1 cultures.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. A secretory phenotype of p63-positive PDA cells that promotes inflammatory gene expression changes in CAFs in vitro.
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inactivation (Figure 2—figure supplement 1O–P). Taken together, these experiments demonstrate
the critical role of p63 in regulating the secretory phenotype in squamous-like models of PDA, which
promotes the induction of inflammation-associated transcriptional changes in CAFs.
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Figure 2. p63 expression in PDA cells drives a secretory phenotype that induces iCAF formation in vitro. (A) Schematic of workflow for generating
conditioned media from SUIT2-empty and SUIT2-p63 cells and subsequent analysis of PSC cultures. (B–C) Bar charts showing RT-qPCR analysis for iCAF
markers (Il6, Cxcl1, Lif) following culture of 2 mouse PSC lines in Matrigel for four days with the indicated conditioned media. (D) RT-qPCR analysis for
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The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. p63 expression in PDA cells drives a secretory phenotype that induces iCAF formation in vitro.
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Ectopic expression of p63 in PDA cells promotes inflammation-
associated transcriptional changes in the tumor microenvironment in
vivo
We next evaluated the relevance of the p63-induced secretory phenotype in an in vivo model of
PDA. For this purpose, we first infected SUIT2-luciferase cells (Somerville et al., 2018) with a p63
cDNA or empty vector prior to orthotopic transplantation into the pancreas of NOD-scid gamma
(NSG) mice. In accordance with our previous findings (Somerville et al., 2018), p63 expression
enhanced the growth of SUIT2 cells in vivo, but not in vitro (Figure 3A–B and Figure 3—figure sup-
plement 1A–D). Importantly, we validated the in vivo-specific growth advantage caused by ectopic
p63 expression in the mM1 organoids following transplantation into the pancreas of C57BL/6 mice
(Figure 3—figure supplement 1E–K). Tumors from the SUIT2 xenograft model were harvested and
subjected to bulk RNA-seq analysis. Mapping of human and mouse transcripts to their respective
genomes allowed us to discriminate the transcriptional changes happening in the human cancer cells
from those of non-neoplastic mouse cells comprising the tumor stroma (Figure 3C).
In the human cancer cell compartment, we identified 633 genes that were significantly upregu-
lated in SUIT2-p63 tumors compared to controls, which largely corresponded to squamous lineage
p63 target genes (e.g. S100A2, KRT5) (Figure 3D, Figure 3—figure supplement 1L and
Supplementary file 3; Bailey et al., 2016; Somerville et al., 2018). Within the mouse stromal com-
partment, we identified 500 genes that were significantly upregulated in SUIT2-p63 tumors com-
pared to controls (Figure 3E and Supplementary file 3). An ontology analysis of this set of genes
revealed enrichment for inflammatory responses, neutrophil degranulation, and cytokine production
as top-ranking gene sets (Figure 3F). Importantly, the transcriptional signature of iCAFs was signifi-
cantly more enriched in the mouse stromal compartment of SUIT2-p63 relative to SUIT2-empty
tumors (Figure 3G), which is consistent with our conditioned media experiments (Figure 2A–D). In
this bulk RNA-seq analysis, the transcriptional signature of myCAFs was modestly depleted in SUIT2-
p63 tumors, although this was not significant (Figure 3—figure supplement 1M). However, fluores-
cent activated cell sorting (FACS) of fibroblasts from these two groups of tumors confirmed an
increase in iCAF markers and a decrease in myCAF markers in the SUIT2-p63 tumors (Figure 3—fig-
ure supplement 1N–P). Flow cytometry analysis confirmed that SUIT2-p63 tumors were more infil-
trated with CD45+CD11b+Ly6G+ neutrophils when compared to control tumors, which is a marker of
enhanced tissue inflammation (Figure 3H–I). iCAF induction and neutrophil infiltration were also cor-
related with pre-existing levels of TP63 expression in human PDA organoid xenografts models (Fig-
ure 3—figure supplement 1Q–T). Moreover, a similar neutrophil infiltration phenotype was
observed in the orthotopic mM1-p63 tumors, which also correlated with a decrease in infiltrating
CD4- and CD8-positive T cells (Figure 3J–K). This finding is consistent with prior evidence that
tumor-associated neutrophils have an immunosuppressive effect in PDA (Bayne et al., 2012;
Chao et al., 2016). Finally, plasma concentrations of the murine cytokine IL-6, a marker of systemic
inflammation and immunosuppression (Flint et al., 2016; Nishimoto and Kishimoto, 2006) that is
largely produced by iCAFs in PDA (Biffi et al., 2019; Elyada et al., 2019; O¨hlund et al., 2017),
were ~10 fold higher in the mice bearing SUIT2-p63 versus SUIT2-empty tumors (Figure 3—figure
supplement 1U). Collectively, these experiments suggest that p63-positive PDA cells induce
enhanced stromal inflammation in vivo when compared to p63-negative tumors.
Knockout of p63 in an orthotopic PDA tumor model attenuates stromal
inflammation
We next addressed the impact of p63 inactivation on the tumor microenvironment in vivo. To this
end, KLM1-Cas9-luciferase cells were transduced with TP63 sgRNAs before transplantation into the
pancreas of NSG mice (Figure 4—figure supplement 1A). By monitoring tumor progression using
bioluminescent imaging, we found that p63 inactivation resulted in a significant reduction in tumor
growth when compared to control tumors (Figure 4A–B), which is consistent with in vivo-specific
growth enhancement caused by acute p63 expression in SUIT2 and mM1 orthotopic models
(Figure 3A–B and Figure 3—figure supplement 1A–K). In order to study the impact of p63 inactiva-
tion on the tumor microenvironment while controlling for overall tumor burden, we allowed sufficient
time for tumors to form in each group before harvesting for analysis when a critical bioluminescent
signal was reached. By this endpoint metric, cells transduced with the two independent TP63
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Figure 3. Ectopic expression of p63 in PDA cells promotes inflammation-associated transcriptional changes in the tumor microenvironment. (A–I)
SUIT2-empty and SUIT2-p63 PDA cells harboring a luciferase transgene were transplanted into the pancreas of NSG mice. (A–B) Quantification of
tumor volume (A) and images of tumors (B) on day 25 post-transplantation. (C) Experimental workflow for RNA-seq analysis of bulk tumor tissue. (D–E)
Heatmap representations of differentially expressed genes that unambiguously map to (D) the human genome and therefore are derived from human
cancer cells or (E) the mouse genome and therefore are derived from mouse stromal cells. Selected genes in each group are listed. Scale bar indicates
standardized expression value. (F) Ontology analysis of the 500 significantly up-regulated mouse genes using Metascape. GO terms are ranked by their
significance (p value) and the most significant terms (-log10 p value > 15) are highlighted. (G) GSEA plot evaluating the iCAF signature in the mouse
stromal compartment of SUIT2-p63 versus SUIT2-empty tumors. (H) Quantification of flow cytometry analysis of CD45+CD11b+Ly6G+ neutrophils and
CD45+CD11b+F4/80+ macrophages from bulk tumor tissues from SUIT2 xenografts. n = 5 mice per group. ***p<0.001 by Student’s t-test. (I)
Representative flow cytometry plots from (H). (J–K) KPC mM1 organoids with a p63 cDNA or empty vector control and transplanted to the pancreas of
C57BL6 mice. (J) Quantification of flow cytometry analysis of CD45+ cells in the tumors. n = 4–5 mice per group. ***p<0.001 by Student’s t-test. (K)
Representative flow cytometry plots from (J). TCRb refers to T cell receptor b.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Ectopic expression of p63 in PDA cells promotes inflammation-associated transcriptional changes in the tumor
microenvironment.
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Figure 4. Knockout of p63 in an orthotopic PDA tumor model attenuates stromal inflammation. (A–E) KLM1-Cas9 cells expressing a luciferase
transgene were infected with two independent p63 or control (sgNEG) sgRNAs and transplanted to the pancreas of NSG mice. (A) Quantification of
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Figure 4 continued on next page
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sgRNAs formed tumors with a significantly longer latency versus controls (Figure 4C). Immunohisto-
chemical analysis for p63 revealed an ‘escaper’ group (sgTP63#2) that gave rise to p63-positive
tumors, suggesting the emergence of p63-positive clones within the pooled population of trans-
planted cells (Figure 4D). However, in the second cohort where p63 was inactivated (sgTP63#4), we
identified largely p63-negative tumors at endpoint, allowing us to interrogate the tumor microenvi-
ronment in a loss of function context (Figure 4D–E and Figure 4—figure supplement 1B).
To achieve this, we FACS-purified human cancer cells, immune cells, and fibroblasts and per-
formed RNA-seq analysis (Figure 4F–I). Within the cancer cell compartment, we identified 459 genes
that were significantly downregulated in the p63-knockout tumors (Figure 4G and
Supplementary file 4). As expected, this included TP63 as well as its downstream target genes,
KRT5, KRT6A and S100A2 (Figure 4G and Figure 4—figure supplement 1C). Within the sorted
fibroblast compartment, we identified 396 genes that were significantly downregulated in the p63-
knockout tumors, which included a significant suppression of the iCAF gene signature (Figure 4H–J
and Supplementary file 4). In contrast, the myCAF gene signature was significantly induced in p63-
knockout tumors (Figure 4—figure supplement 1D). Finally, within the sorted immune cell fraction
we identified 463 genes that were significantly down-regulated in the p63-knockout tumors, which
was enriched for markers of neutrophils, such as Ly6g, Mpo, S100a8, S100a9 and Cxcr2 (Figure 4I–K
and Supplementary file 4). We confirmed reduced neutrophil infiltration in the p63 knockout tumors
by immunofluorescence staining for LY6G and myeloperoxidase (MPO) (Figure 4—figure supple-
ment 1E–H). Taken together, these findings demonstrate that inactivation of p63 dampens the
inflammation-associated transcriptional response present in the CAF and immune compartments of
the stroma.
The findings above led us to investigate whether p63-expressing PDA cells can collaborate with
CAFs to increase neutrophil infiltration. In order to model this in vitro, we established a co-culture
system in which human SUIT2-empty or SUIT2-p63 cells were cultured in Matrigel either alone or in
combination with mouse PSCs (Figure 4L). RT-qPCR analysis for murine-specific transcripts con-
firmed that SUIT2-p63 cells augmented the iCAF phenotype versus controls in this co-culture system
(Figure 4—figure supplement 1I). Of note, this included a marked upregulation of the iCAF gene
Cxcl1, which encodes an established neutrophil chemoattractant (Moser et al., 1990). We found
that the SUIT2-p63/PSC co-cultures released soluble factors that increased the chemotaxis of pri-
mary mouse neutrophils and, importantly, this phenotype was enhanced in the SUIT2-p63/PSC co-
culture as compared to each cell type individually (Figure 4M–N and Figure 4—figure supplement
1J). Of note, we found that conditioned media from p63-expressing PDA cells could also promote a
modest degree of neutrophil recruitment in the absence of co-cultured PSCs (Figure 4—figure sup-
plement 1K-M). This effect was dependent on CXCL1 (Figure 4—figure supplement 1K-M), which
is a p63 target gene in PDA cells (see below). Taken together, these experiments suggest that p63-
Figure 4 continued
(A). (C) Table summarizing the median time mice from each group were sacrificed and the tumor volume at endpoint. Endpoint was determined as a
bioluminescence signal >3109 p/s for each individual mouse. **p<0.01 by log rank (Mantel-Cox) test. (D) Quantification of p63 expression as
determined by immunohistochemical staining of tumors from the indicated experimental groups. n = 4–5 mice per group. ***p<0.001 by one-way
ANOVA with Tukey’s test for multiple comparisons. (E) Representative images from (D). Scale bar indicates 50 mm. (F) Schematic of experimental
workflow and sorting strategy for enriching for human cancer cells, mouse fibroblasts and mouse immune cells and subsequent RNA-seq analysis. (G–I)
Heatmap representations of differentially expressed genes from the human cancer cell compartment (G), mouse fibroblast compartment (H) and mouse
immune compartment (I) and the indicated tumor samples. Selected genes in each group are listed. Scale bar indicates standardized expression value.
(J) GSEA plot evaluating the iCAF signature in the mouse fibroblast compartment of p63-positive versus control (sgNEG) tumors. (K) Ontology analysis
of the 463 significantly down-regulated mouse genes from immune compartment using Metascape. GO terms are ranked by their significance (p value)
and the most significant term (-log10 p value > 15) is highlighted. (L–N) SUIT2-empty or SUIT2-p63 cells were cultured in isolation or together with
mouse PSCs in Matrigel for four days before conditioned media was harvested and used for a trans-well migration assay with freshly isolated mouse
neutrophils. (L) Schematic of experimental workflow. (M) Quantification of trans-well neutrophil migration in the indicated media conditions as
determined by confocal imaging. Mean+ SEM is shown. Results are presented as the mean number of invading neutrophils per 10 random fields for
each condition and are representative of n = 3 biological replicates. ***p<0.001, **p<0.01 by two-way ANOVA with Sidak’s test for multiple
comparisons. All significant interactions are shown. (N) Representative confocal images from (M).
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. Knockout of p63 in an orthotopic PDA tumor model attenuates the inflammatory signature of fibroblasts and immune cells.
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positive PDA cells possess a secretory phenotype that can promote neutrophil migration, which can
be further enhanced by the presence of PSCs/iCAFs.
p63 activates enhancer elements and transcription of genes encoding
pro-inflammatory cytokines in PDA cells
We next sought to define a molecular mechanism by which p63 drives a pro-inflammatory secretory
phenotype by interrogating the transcriptional changes that occur following ectopic p63 expression
in SUIT2 cells (Somerville et al., 2018). GSEA comparing SUIT2-p63 to SUIT2-empty cells revealed
the activation of a number of inflammation-related pathways as top-ranking gene sets following p63
expression (Figure 5A–C and Figure 5—figure supplement 1A). Of note, a number of these path-
ways (e.g. NF-kB and JAK/STAT3 signaling) overlapped with those activated in iCAFs (Biffi et al.,
2019). Next, we interrogated the transcriptional changes of inflammatory genes that occur following
acute p63 inactivation in BxPC3 cells, a human PDA cell line that expresses p63 at high levels
(Somerville et al., 2018). These analyses identified IL1A, IL1B, CXCL1, CXCL8, CSF2 (GM-CSF),
CCL20, AREG, FJX1, and ADORA2B as the top inflammation-related genes regulated by p63
(Figure 5C and Figure 5—figure supplement 1B). Importantly, an analysis of p63 over-expression
and knockout/knockdown RNA-seq datasets performed in nine different human PDA lines or orga-
noids (Somerville et al., 2018) revealed that this group of inflammatory genes is regulated by p63
across these different contexts, albeit with a degree of heterogeneity (Figure 5D and Figure 5—fig-
ure supplement 1C). Chromatin immunoprecipitation followed by DNA sequencing (ChIP-seq) anal-
ysis performed in BxPC3 cells revealed that each of these genes is located near a p63-bound
enhancer element, suggesting direct transcriptional regulation (Figure 5—figure supplement 1D).
Among these p63 targets, IL1A and IL1B were outliers, as their expression was the most affected by
p63 perturbation (Figure 5D). ChIP-seq analysis revealed a p63-induced super-enhancer located at
an intergenic region between the IL1A and IL1B genes (Figure 5E and Figure 5—figure supplement
1E–H). Using CRISPR-interference to target this region for inactivation (Qi et al., 2013), we verified
that this group of p63-bound enhancers was responsible for activating IL1A and IL1B expression
(Figure 5E–F and Figure 5—figure supplement 1I). Taken together, these findings suggest that
p63 promotes enhancer-mediated transcriptional activation of genes encoding secreted factors with
established roles in promoting inflammation.
IL-1a is the key secreted molecule induced by p63 in PDA cells that
promotes iCAF induction in vitro
We focused our subsequent functional experiments on IL1A and IL1B, which respectively encode
interleukin one alpha (IL-1a) and beta (IL-1b) and are important mediators of inflammatory
responses, including NF-kB signaling that we found to be upregulated following p63 expression
(Figure 5B and Figure 5—figure supplement 1A; Di Paolo and Shayakhmetov, 2016;
Dinarello and Wolff, 1993). We recently demonstrated a critical role for IL-1 in promoting the
induction of iCAFs through the indirect activation of JAK/STAT signaling (Biffi et al., 2019). In order
to assess whether IL-1a and IL-1b are secreted by p63-expressing PDA cells, we performed enzyme-
linked immunosorbent assay (ELISA) experiments for these two proteins on conditioned media fol-
lowing p63 knockout in KLM1 cells. This assay efficiently detected IL-1a, but not IL-1b, in the control
setting and the levels of secreted IL-1a were significantly reduced by two independent TP63 sgRNAs
(Figure 5G). An absence of IL-1b secretion in this context might be due to a lack of inflammasome
activation, which is a known requirement for IL-b, but not IL-a secretion (Di Paolo and Shayakhme-
tov, 2016). Consistent with this observation, ectopic expression of p63 in SUIT2 cells led to robust
secretion of IL-1a, but not IL-1b, and this effect could be ablated by CRISPR-interference-mediated
targeting of the IL1 super-enhancer (Figure 5H–I). Taken together, these results indicate that both
IL1A and IL1B are regulated by p63 at the transcriptional level, but only IL-1a is secreted at detect-
able levels by p63-expressing PDA cells in vitro.
In order to investigate whether p63-driven iCAF induction is conferred via an IL-1-mediated sig-
naling mechanism, we used mouse PSC lines in which the IL-1 receptor (Il1r1) was knocked out using
CRISPR (Biffi et al., 2019) and performed experiments with conditioned media harvested from
SUIT2-p63 or SUIT2-empty cells. Consistent with the results above, PSCs infected with the control
sgRNA displayed a marked increase in iCAF gene expression following culture in SUIT2-p63
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Figure 5. p63 activates enhancer elements and transcription of genes encoding pro-inflammatory cytokines in PDA cells. (A–B) GSEA plots evaluating
the indicated Hallmark gene signatures upon p63 expression in SUIT2 cells. (C) Scatter plot shows the mean log2 fold change of expressed genes upon
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Figure 5 continued on next page
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conditioned media (Figure 5J–K and Figure 5—figure supplement 1J–K). However, this induction
was absent in the IL-1 receptor knock out lines (Figure 5J–K and Figure 5—figure supplement 1J–
K). Finally, we confirmed the dependency on IL-1 signaling for p63 driven iCAF induction by per-
forming conditioned media experiments using SUIT2-p63 cells following inactivation of the IL1
super-enhancer via CRISPR interference (Figure 5L and Figure 5—figure supplement 1L). These
data demonstrate that p63 expressing PDA cells induce an iCAF phenotype via paracrine IL-1a
signaling in vitro.
Squamous trans-differentiation of human PDA tumors correlates with
increased inflammatory fibroblasts and neutrophil infiltration in patient
samples
In order to ascertain whether p63 expression is associated with stromal inflammation changes in
human pancreatic cancer patients, we first interrogated three independent datasets that have pro-
filed the transcriptome of bulk tumor tissue (Bailey et al., 2016; Cancer Genome Atlas Research
Network, 2017; Moffitt et al., 2015). In all three datasets, the expression of IL1A was found to be
significantly elevated in TP63high versus TP63low patient samples (Figure 6A). Of note, it is the DN
isoform of TP63 that is overexpressed in squamous-subtype PDA tumors (Bailey et al., 2016). We
next interrogated single-cell RNA-seq data from 24 human PDA tumors and 11 normal pancreas tis-
sue samples from a recently published study (Peng et al., 2019). This analysis confirmed that TP63 is
aberrantly expressed in the ductal compartment of a subset of patient samples that exhibit high-
level expression of squamous marker genes (Figure 6B–C and Figure 6—figure supplement 1A–B).
Importantly, we observed significantly higher expression of inflammatory genes (CXCL1, IL6 and LIF)
within the fibroblast compartment in TP63high versus TP63low patients (Figure 6D and Figure 6—fig-
ure supplement 1C). Finally, we performed a multiplex immunofluorescence staining of 12 human
PDA tissue samples, which revealed a trend towards increased neutrophil infiltration in p63-positive
versus p63-negative PDA samples (Figure 6E–F and Figure 6—figure supplement 1D).
Discussion
Prior studies have revealed PDA to be a heterogeneous disease at the molecular level with respect
to both the tumor and stromal compartments (Bailey et al., 2016; Cancer Genome Atlas Research
Network, 2017; Collisson et al., 2011; Moffitt et al., 2015). As both compartments are comprised
of cell types that display phenotypic plasticity (O¨hlund et al., 2017; Yuan et al., 2019), dissecting
the molecular cross-talk between cells that define each patient’s tumor remains a formidable chal-
lenge. Although prior studies have made correlations between epithelial and stromal transcriptomes
Figure 5 continued
Heatmap shows gene expression changes in those genes shown in (C) in the indicated cell lines following p63 over-expression (left panel) or knockout/
knockdown (right panel). Scale bar indicates mean log2 fold change versus control. (E) ChIP-seq profiles of p63 (top track) and H3K27ac (bottom four
tracks) following p63 knockout in BxPC3 cells or overexpression in SUIT2 cells surrounding the IL1 locus. The H3K27ac regions identified as a super
enhancer by ROSE analysis are indicated along with the positions of sgRNAs targeting this enhancer used for experiments shown in (F) and (I). (F) RT-
qPCR analysis for IL1A and IL1B in SUIT2-empty or SUIT2-p63 cells infected with dCas9 fused with the KRAB repression domain and the indicated
sgRNAs. The positions of the sgRNAs targeting the IL1 super enhancer are shown in (E). (G–H) ELISA for IL-1a and IL-1b from conditioned media
harvested from KLM1-Cas9 cells infected with the indicated sgRNA (G) or from SUIT2-empty and SUIT2-p63 cells (H). (I) ELISA for IL-1a in SUIT2-empty
or SUIT2-p63 cells infected with dCas9 fused with the KRAB repression domain and the indicated sgRNAs. (J–K) Bar charts showing RT-qPCR analysis
for iCAF markers (Il6, Cxcl1, Lif) following culture of clones of two mouse PSC lines from which the IL-1 receptor was clonally knocked out with CRISPR
in Matrigel for four days with conditioned media from SUIT2-empty or SUIT2-p63 cells. (L) Bar charts showing RT-qPCR analysis for iCAF markers (Il6,
Cxcl1, Lif) following culture of PSCs in Matrigel for four days with the conditioned media harvested from cells shown in (I). For all experiments, control
media represent DMEM supplemented with 5% FBS. Mean+ SEM is shown. For RT-qPCR experiments, results are presented as the mean of three
technical replicates and are representative of n = 3 biological replicates and ***p<0.001, **p<0.01, *p<0.05 by one-way ANOVA with Dunnett’s test for
multiple comparisons. For each ELISA experiment, n = 3 biological replicates and ***p<0.001, **p<0.01, *p<0.05 by one-way ANOVA with Tukey’s test
for multiple comparisons. ns = not significant.
The online version of this article includes the following figure supplement(s) for figure 5:
Figure supplement 1. p63 activates enhancer elements and transcription of genes encoding pro-inflammatory cytokines in PDA cells.
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in PDA (Maurer et al., 2019; Moffitt et al., 2015; Puleo et al., 2018), it remains unclear whether
the evolution of these two compartments is dependent on one another.
Here, we have defined a mechanism by which tumor cells gain an ability to reprogram their local
microenvironment through the acquisition of p63, which is a master regulator of the squamous sub-
type of PDA (Hamdan and Johnsen, 2018; Somerville et al., 2018). Mechanistically, we have shown
that p63 activates a pro-inflammatory secretory phenotype that triggers iCAF induction through an
IL-1-dependent signaling mechanism. Importantly, we have verified the correlation between TP63
and IL1A expression in three independent transcriptome studies of human PDA tumors. In addition,
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Figure 6. Squamous trans-differentiation of PDA cells correlates with increased inflammatory fibroblasts and neutrophil infiltration in patient samples.
(A) Quantification of IL1A mRNA levels in the indicated studies. Each dot represents one patient sample, and patients were stratified as TP63high or
TP63low as described in Somerville et al. (2018). (B–D) Single cell RNA-seq data from 24 primary PDA tumor and 11 normal pancreas samples from the
study by Peng et al. (2019). (B) 24 primary PDA tumor samples ranked by mean TP63 expression levels across all cell types. Patients were stratified as
TP63high (n = 4) or TP63low (n = 4) as shown. (C) Expression of squamous genes in ductal cells from TP63high or TP63low PDA patient samples from (B).
(D) Expression of inflammatory genes (IL6, CXCL1 and LIF) in stellate cells and fibroblast cells from TP63high or TP63low PDA patient samples from (B).
Each dot represents a single cell and the four patient samples were pooled for this analysis. (E–F) Multiplex immunofluorescent staining of primary
pancreatic cancer tumor from the Rapid Autopsy Program. (E) Quantification of p63, MPO, aSMA and MUC1 in p63-negative (p63neg, n = 6) and p63-
positive (p63pos, n = 6) samples. (F) Representative images of a p63-positive PDA tumor stained with DAPI (blue), MPO (orange), aSMA (white), MUC1
(green), p63 (red), and overlaid (merge). The images were collected from the same tumor area, but over multiple rounds of iterative staining. Scale bar
indicates 20 mm. For (A), (C) and (D) ***p<0.001, **p<0.01 by Student’s t-test. ns, not significant.
The online version of this article includes the following figure supplement(s) for figure 6:
Figure supplement 1. p63 expression in PDA cells is associated with inflammatory CAF induction and neutrophil infiltration in patient samples.
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in independent studies of primary PDA patient samples, we have shown that squamous trans-differ-
entiation of human pancreatic cancer cells is associated with an enhanced inflammatory CAF pheno-
type and increased neutrophil infiltration. A recent transcriptome study of human tissue samples also
revealed a correlation between squamous-subtype PDA tumors and inflammation-associated
changes in the stroma (de Santiago et al., 2019), which validates that our observations in experi-
mental models are in accord with clinical observations. While the aberrant expression of p63 confers
a myriad of tumor cell-intrinsic phenotypes in PDA, such as enhanced motility, invasion, and resis-
tance to cytotoxic chemotherapy (Danilov et al., 2011; Somerville et al., 2018), our work points to
a powerful non cell-autonomous effect of p63 in PDA in promoting stromal inflammation.
We previously demonstrated that IL-1/JAK/STAT signaling is the key pathway responsible for
iCAF formation in PDA (Biffi et al., 2019). While a basal level of IL-1 is expressed in PDA tumor cells
that lack p63 expression (Biffi et al., 2019; Tjomsland et al., 2011; Zhang et al., 2018), a key find-
ing in our current study is in demonstrating that a striking heterogeneity exists in IL-1 expression in
the human disease, with the highest levels being found in p63-expressing squamous-subtype
tumors. We account for this observation by demonstrating that a super-enhancer is installed by p63
at the IL1 locus, which enables a > 30 fold increase in IL-1a secretion to enhance iCAF formation.
One expected outcome of p63-mediated IL1A hyperactivation would be a strengthened concentra-
tion gradient of IL-1a emanating from tumor cells to promote iCAF induction within the stroma.
Whilst this hypothesis is robustly supported in the current study, our in vitro and in vivo studies,
together with single cell RNA-seq analysis of PDA patient tumors, suggest that with increasing com-
plexity of the tumor microenvironment, the association of p63 expression in PDA cells with myCAF
abundance is more variable. While the abundance and spatial localization of iCAFs and myCAFs are
likely regulated by several signaling pathways (e.g. TGF-b), our in vivo findings suggest that the
acquisition of p63 expression in the tumor leads to a potent increase in IL-1 secretion to drive iCAF
enrichment in the surrounding microenvironment. Interestingly, a recent study identified a critical in
vivo role for tumor cell-derived IL-1b in inflammatory CAF activation and immune suppression using
murine orthotopic models of PDA (Das et al., 2020). Mechanistically, the expression of IL-1b in vivo
was shown to be driven by toll-like receptor 4 (TLR4) activation and subsequent engagement of the
NLRP3 inflammasome. Taken together with our findings, these data suggest that the transcriptional
activation of both IL1A and IL1B may be functionally relevant within the tumor microenvironment of
squamous-subtype PDA tumors.
Many of the genes regulated by p63 in PDA cells correspond to those activated by the pro-
inflammatory transcription factor NF-kB. Indeed, it has been previously shown that p63 and NF-kB
co-occupy a common set of target genes in head and neck squamous cell carcinoma, and this is
associated with enhanced inflammation in vivo (Yang et al., 2011). In addition, NF-kB is often consti-
tutively active in most pancreatic cancer tissues and confers resistance to apoptosis (Dong et al.,
2002; Wang et al., 1999). In this context, constitutive activation of NF-kB requires an IL-1a-driven
feed-forward amplification loop to promote PDA development (Ling et al., 2012; Niu et al., 2004).
Maintenance of an inflamed CAF state has also been shown to be dependent on the NF-kB signaling
pathway (Biffi et al., 2019; Erez et al., 2010). Taken together, these studies raise the possibility
that p63 functions as an amplifier of NF-kB transcriptional output to drive enhanced secretion of
inflammatory mediators in squamous-subtype PDA tumors. In addition to IL-1a, p63 promotes
expression of other pro-inflammatory cytokines that have been implicated in the development and
progression of PDA, such as CXCL1 and GM-CSF (Bayne et al., 2012; Li et al., 2018; Pylayeva-
Gupta et al., 2012). Notably, both of these cytokines are also produced by iCAFs (O¨hlund et al.,
2017), suggesting that the pro-tumorigenic effects of these factors would be amplified by IL-1a-
mediated crosstalk between p63-expressing tumor cells and iCAFs.
An association between squamous cell carcinomas and infiltrating inflammatory cells has been
observed previously in other tumor contexts (Andreu et al., 2010; Coussens et al., 1999;
Erez et al., 2010; Eruslanov et al., 2014; Ferone et al., 2016; Kargl et al., 2017; Xu et al., 2014;
Yang et al., 2011). In one study, squamous trans-differentiation in a lung adenocarcinoma mouse
model was associated with neutrophil infiltration and other markers of inflammation
(Mollaoglu et al., 2018). In this context, inflammatory changes were promoted by the squamous
lineage transcription factor SOX2 through activation of CXCL5 expression (Mollaoglu et al., 2018).
It is interesting to note that we also observed a correlation between TP63 and SOX2 expression in
single cell RNA-seq analysis of tumor ductal cells from PDA patent samples. Taken together with our
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findings, these results suggest that inflammation is more generally associated with squamous lineage
tumors through multiple distinct mechanisms. Interestingly, a major function of the normal squamous
epithelium is to serve as a protective barrier to exogenous insults. As such, inflammatory pathways
must be tightly regulated and poised for a rapid response in these tissues. Notably, squamous cells
of the epidermis are known to express large amounts of IL-1a at steady state (Hauser et al., 1986)
and IL1A is known to be a key p63 target in normal human keratinocytes (Barton et al., 2010). For
this reason, amplified inflammation may be an inevitable consequence of tumor trans-differentiation
into the squamous lineage in diverse tissue contexts.
Histopathological definitions of PDA are often imprecise and offer limited clinical utility with
respect to patient management and treatment selection (Klo¨ppel and Lu¨ttges, 2001). Adenosqua-
mous carcinoma, for example, is defined by those tumors exhibiting >15% squamous differentiation
and is considered an uncommon variant of PDA. Studies that have identified molecular subtypes of
PDA using transcriptomic analyses provide the opportunity to define a new molecular taxonomy for
pancreatic cancer that is more clinically applicable (Collisson et al., 2019). The challenge now is to
understand the underlying biology that renders these molecular subtypes phenotypically distinct
and to identify robust markers for prospective patient stratification. The findings presented in our
study point to p63 as a functional biomarker that identifies a poor prognostic subgroup of PDA
patients in which inflammatory pathways are amplified. As such, these patients may benefit from tar-
geted therapies that aim to dampen the inflammatory response. For example, monoclonal antibod-
ies targeting IL-1a or IL-1b have shown promise as potential cancer therapies (Hickish et al., 2017;
Hong et al., 2014; Ridker et al., 2017), and the IL-1 receptor antagonist Anakinra has shown effi-
cacy in pre-clinical models of PDA (Zhuang et al., 2016). The findings presented in this study sug-
gest that such agents may also show efficacy in appropriately stratified PDA patients.
Materials and methods
Key resources table
Reagent type
(species) or resource Designation
Source or
reference Identifiers Additional information
Genetic reagent
(Mus. musculus)
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) The
Jackson
Laboratory
Stock #: 005557,
RRID:IMSR_JAX:005557
Genetic reagent
(Mus. musculus)
C57BL/6J The
Jackson
Laboratory
Stock #: 000664,
RRID:IMSR_JAX:000664
Cell line
(Homo sapiens)
PANC1 ATCC Cat# CRL-1469,
RRID:CVCL_0480
Cell line
(Homo sapiens)
PATU8988S DSMZ Cat# ACC-204,
RRID:CVCL_1846
Cell line
(Homo sapiens)
SUIT2 JCRB JCRB1094,
RRID:CVCL_3172
Cell line
(Homo sapiens)
CFPAC1 ATCC Cat# CRL-1918,
RRID:CVCL_1119
Cell line
(Homo sapiens)
AsPC1 ATCC CRL-1682,
RRID:CVCL_0152
Cell line
(Homo sapiens)
PANC0403 ATCC Cat# CRL-2555,
RRID:CVCL_1636
Cell line
(Homo sapiens)
CAPAN2 ATCC Cat# HTB-80,
RRID:CVCL_0026
Cell line
(Homo sapiens)
HPAFII ATCC Cat# CRL-1997,
RRID:CVCL_0313
Cell line
(Homo sapiens)
MIAPaca2 ATCC Cat# CRL-1420,
RRID:CVCL_0428
Cell line
(Homo sapiens)
BxPC3 ATCC Cat# CRL-1687,
RRID:CVCL_0186
Continued on next page
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Continued
Reagent type
(species) or resource Designation
Source or
reference Identifiers Additional information
Cell line
(Homo sapiens)
T3M4 RCB Cat# RCB1021,
RRID:CVCL_4056
Cell line
(Homo sapiens)
KLM1 RCB Cat# RCB2138,
RRID:CVCL_5146
Cell line
(Homo sapiens)
Human PSCs PMID:30366930 Primary
Cell line
Mus musculus
mPSC4; mPSC5 PMID:30366930 Primary
Cell line
Mus musculus
mM1 PMID:25557080 Primary
Antibody anti-p63
(rabbit monoclonal)
Cell Signaling Cat# 39692,
RRID:AB_2799159
1:1000 (WB)
1:500 (IHC)
1:500 (IF)
Antibody anti-HSC70
(mouse monoclonal)
Santa
Cruz Biotechnology
Cat# sc-7298,
RRID:AB_627761
1:5000 (WB)
Antibody anti-ACTB
(mouse monoclonal)
Sigma-Aldrich Cat# A3854,
RRID:AB_262011
1:1000 (WB)
Antibody anti-Cas9
(mouse monoclonal)
Epigentek Cat# A-9000–050,
RRID:AB_2828022
1:1000 (WB)
Antibody anti-MPO
(goat polyclonal)
R and D Systems Cat# AF3667,
RRID:AB_2250866
1:200 (IF)
Antibody anti-LY6G
(rat monoclonal)
BD Pharmingen Cat# 551459,
RRID:AB_394206
1:200 (IF)
Antibody anti-MPO
(rabbit polyclonal)
Abcam Cat# ab9535,
RRID:AB_307322
1:200 (IF)
Antibody anti-alpha-SMA (mouse
monoclonal)
Sigma-Aldrich Cat# A2547,
RRID:AB_476701
1:200 (IF)
Antibody anti-Muc1 (Armenian
hamster monoclonal)
Abcam Cat# ab80952,
RRID:AB_1640314
1:200 (IF)
Antibody anti-CD45-PerCP-Cy5-5
(rat monoclonal)
BioLegend Cat# 103132,
RRID:AB_893340
1:100 (FC)
Antibody anti-PDPN-APC/Cy7
(Syrian hamster
monoclonal)
BioLegend Cat# 127418,
RRID:AB_2629804
1:100 (FC)
Antibody anti-CD326 (EPCAM)-
AlexaFluor
647 (mouse monoclonal)
BioLegend Cat# 324212,
RRID:AB_756086
1:100 (FC)
Antibody anti-E-Cadherin-
AlexaFluor
647 (rat monoclonal)
BioLegend Cat# 147304,
RRID:AB_2563040
1:100 (FC)
Antibody anti-CD45-BV510
(rat monoclonal)
BioLegend Cat# 103138,
RRID:AB_2563061
1:100 (FC)
Antibody anti-F4/80-BV785
(rat monoclonal)
BioLegend Cat# 123141,
RRID:AB_2563667
1:100 (FC)
Antibody anti-Ly6G/Ly6C (Gr-1)-
PE (rat monoclonal)
BioLegend Cat# 108408,
RRID:AB_313373
1:100 (FC)
Antibody anti-CD11b-PE-Cy7
(rat monoclonal)
BioLegend Cat# 101216,
RRID:AB_312799
1:500 (FC)
Antibody anti- CD8a-APC-Cy7
(rat monoclonal)
BioLegend Cat# 100714,
RRID:AB_312753
1:100 (FC)
Antibody anti-CD4-APC
(rat monoclonal)
BioLegend Cat# 100516,
RRID:AB_312719
1:100 (FC)
Continued on next page
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Continued
Reagent type
(species) or resource Designation
Source or
reference Identifiers Additional information
Antibody anti-TCRb-PE-Cy7
(Armenian hamster
monoclonal)
BioLegend Cat# 109222,
RRID:AB_893625
1:500 (FC)
Antibody Anti-CD11b-AlexaFluor
488 (rat monoclonal)
BioLegend Cat# 101217,
RRID:AB_389305
1:100 (FC)
Antibody anti-CXCL1
(mouse monoclonal)
R and D Systems Cat# MAB275,
RRID:AB_2292460
10 mg/ml
Antibody IgG2B Isotype Control
(mouse monoclonal)
R and D Systems Cat# MAB004,
RRID:AB_357346
10 mg/ml
Recombinant
DNA reagent
LentiV-Cas9-puro Addgene Cat# 108100
Recombinant
DNA reagent
LRNG vector Addgene Cat# 125593
Recombinant
DNA reagent
Lenti-dCas9-
KRAB-blast
Addgene Cat# 89567
Recombinant
DNA reagent
YXP-Cas9-puro This paper See ‘CRISPR-based Targeting’ in Materials
and methods
Recombinant
DNA reagent
Lenti-luciferase-
blast vector
PMID:30428345
Recombinant
DNA reagent
LentiV-DNp63-
neo vector
PMID:30428345
Peptide,
recombinant protein
mouse CXCL1 Peprotech Cat# 250–11
Peptide,
recombinant protein
human CXCL1 Peprotech Cat# 300–11
Commercial
assay or kit
IL-1a ELISA assay R and D Systems Cat# DLA50
Commercial
assay or kit
IL-1b ELISA assay R and D Systems Cat# DLB50
Commercial
assay or kit
IL-6 ELISA assay R and D Systems Cat# M6000B
Other Matrigel Corning Cat# 356231
Other 3 mm FluoroBlok
cell culture insert
Corning Cat# 08-772-141
Software, algorithm HISAT2 PMID:25751142 HISAT2,
RRID:SCR_015530
Software, algorithm Cuffdiff PMID:20436464 Cuffdiff,
RRID:SCR_001647
Software, algorithm Morpheus Broad Institute Morpheus by
Broad Institute,
RRID:SCR_017386
Software, algorithm Metascape PMID:30944313 Metascape,
RRID:SCR_016620
Software, algorithm GSEA PMID:16199517 Gene Set
Enrichment Analysis,
RRID:SCR_003199
Software, algorithm DESeq2 PMID:25516281 DESeq2,
RRID:SCR_015687
Software, algorithm SAMtools 1.4 PMID:19505943 SAMTOOLS,
RRID:SCR_002105
Cell lines and cell culture
Mouse PSCs and pancreatic organoid lines were previously described (Boj et al., 2015;
O¨hlund et al., 2017). Human PSCs were purchased from ScienCell (3830). Mouse PSCs in which the
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Il1r1 was knocked out using CRISPR were previously described (Biffi et al., 2019). Mouse and human
PSCs were cultured in DMEM (10–013-CV; Fisher Scientific) containing 5% FBS. HEK 293 T cells were
cultured in DMEM containing 10% FBS. Human PDA cell lines were cultured in RPMI 1640 (Gibco)
containing 10% FBS. All cells were cultured with 1% L-glutamine and 1% Penicillin/Streptomycin at
37˚C with 5% CO2. All cell lines were routinely tested for mycoplasma and were authenticated using
STR profiling. For conditioned media experiments, human PDA cell lines or mouse organoids were
cultured for 3–4 days in DMEM containing 5% FBS before media were collected and filtered through
a 0.45 mm syringe filter to remove debris. Conditioned media were stored at 4˚C for no more than
3–4 days or snap frozen and stored at  80˚C prior to use.
Lentiviral production and infection
Lentivirus was produced in HEK 293 T cells by transfecting plasmid DNA and packaging plasmids
(VSVG and psPAX2) using Polyethylenimine (PEI 25000; Polysciences; Cat# 23966–1). Media were
replaced with target media 6–8 hr following transfection and lentivirus-containing supernatant was
subsequently collected every 12 hr for 48 hr prior to filtration through a 0.45 mm filter. For infection
of human PDA cells, cell suspensions were mixed with lentiviral-containing supernatant supple-
mented with polybrene to a final concentration of 4 mg/ml. Cells were plated in tissue culture plates
of the appropriate size and lentiviral-containing supernatant was replaced with fresh media after an
incubation period of 24 hr. For infection of pancreatic organoids, lentivirus was first concentrated
10x in mouse organoid media (Boj et al., 2015) using Lenti-X concentrator according to the manu-
facturer’s instructions. Organoid cultures were then dissociated into single cells, and spinoculated by
centrifugation as described previously (Roe et al., 2017).
CRISPR-based targeting
To generate cell lines in which TP63 had been stably knocked out, KLM1 cells expressing Cas9 in the
LentiV-Cas9-puro vector (addgene # 108100) were infected in a pooled fashion with control or p63
sgRNAs in the LRNG vector (Roe et al., 2017). Two days post infection with sgRNAs, transduced
cells were selected with 1 mg/ml of G418 for five days before they were used for conditioned media
experiments or orthotopic transplantations. For GFP-depletion assays, KLM1 and T3M4 cells were
infected with sgRNAs as described above but without selection and GFP% was measured on day
three (P0) and then every three days post-viral transduction until day 18 (P5). For CRISPR interfer-
ence at the IL1 enhancer, SUIT2-empty or SUIT2-p63 cells stably expressing catalytically-dead Cas9
fused with a KRAB repression domain in the Lenti-dCas9-KRAB-blast vector (addgene #89567) were
infected in a pooled fashion with sgRNAs targeting IL1 enhancer regions (identified from p63 and
H3K27ac ChIP-seq in these lines) in the LRNG vector. Stable cell lines were selected by G418 selec-
tion for seven days prior to their use in conditioned media experiments. For doxycycline-inducible
CRISPR based targeting of p63 in T3M4 and KLM1 cells, Cas9 from the LentiV-Cas9-puro vector was
cloned into the doxycycline-regulated TREtight-cDNA-EFS-rtTA-P2A-Puro vector (Somerville et al.,
2018) to generate the YXP-Cas9-puro vector. T3M4 and KLM1 cells were infected with the YXP-
Cas9-puro vector, selected with 3 mg/ml puromycin to generate stable cell line before infection with
sgRNAs targeting TP63 (sgTP63#4) or a control sgRNA (sgNEG) in LRNG vector. Two days post
infection with sgRNAs, transduced cells were selected with 1 mg/ml of G418 for three days and
were subsequently treated with doxycycline (1 mg/ml) for 48 hr prior to harvesting RNA and lysate
for RNA-seq and western blot analysis, respectively. sgRNA sequences can be found in
Supplementary file 5.
RNA extraction and RT-qPCR analysis
Total RNA was extracted using TRIzol reagent following the manufacturer’s instructions. For RNA
extraction from cells cultured in Matrigel, cells were lysed by adding TRIzol reagent directly to the
Matrigel dome. 200 ng-1mg of total RNA was reverse transcribed using qScript cDNA SuperMix
(Quanta bio; 95048–500), followed by RT-qPCR analysis with Power SYBR Green Master Mix (Thermo
Fisher Scientific; 4368577) on an ABI 7900HT fast real-time PCR system. Gene expression was nor-
malized to GAPDH or Gapdh for human and murine gene expression analysis, respectively. RT-qPCR
primers used can be found in Supplementary file 5.
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Cell lysate preparation and western blot analysis
Cell cultures were collected and 1 million cells were counted by trypan blue exclusion and washed
with ice cold PBS. Cells were then resuspended in 100 ml PBS and lysed with 100 ml of 2x Laemmli
Sample Buffer supplemented with b-mercaptoethanol by boiling for 30 min. Samples were centri-
fuged at 4˚C for 15 min at 10,000xg and the supernatant was used for western blot analysis with
standard SDS-PAGE-based procedures. Primary antibodies used were p63 (Cell Signaling; 39692),
HSC70 (Santa Cruz; sc-7298), ACTB (Sigma-Aldrich; A3854) and Cas9 (Epigentek; A-9000–050) and
proteins were detected using HRP-conjugated secondary antibodies.
Elisa
For ELISA of plasma, blood was harvested via cardiac puncture from anesthetized mice at end point
and plasma separated by centrifugation. For ELISA of media, conditioned media was harvested as
described above. ELISA assays used were IL-1a (DLA50; R and D Systems), IL-1b (DLB50; R and D
Systems) and IL-6 (M6000B; R and D Systems).
In Vitro luciferase imaging
To generate luciferase expressing mouse PSC cultures, cells were infected with a luciferase trans-
gene in a Lenti-luciferase-blast vector (Somerville et al., 2018) and stable cell lines were generated
by selection with 10 mg/ml blasticidin. Cells were plated at a density of 10,000 cells per 20 ml of
Matrigel in each well of a black, clear-bottom, ultra-low attachment 96-well plate (10014–318; CELL-
STAR) and 200 ml of conditioned media was added. Cells were imaged following four days of culture
using an IVIS Spectrum system (Caliper Life Sciences) six minutes post addition of D-Luciferin (150
mg/ml) to each well. For luciferase-based proliferation assays of SUIT2-p63 cells in vitro, parental
SUIT2 cells were first infected with Lenti-luciferase-blast vector and stable SUIT2-luciferase cell lines
were generated by selection with 10 mg/ml blasticidin. SUIT2-luciferase cells were then infected with
p63 cDNA in LentiV-DNp63-neo vector (Somerville et al., 2018) or the empty vector as a control.
Two days post infection, transduced cells were selected with 1 mg/ml of G418 and on day seven
post infection, cells were counted by trypan blue exclusion and seeded at a density of 500 cells per
well in 200 ml of media in black 96-well plates (137101; Thermo). Cells were imaged daily as
described above.
In Vivo orthotopic transplantations and bioluminescence imaging
Transplantation of human PDA cells and mouse pancreatic organoid cultures have been described
previously (Boj et al., 2015; Somerville et al., 2018). For transplantation of human cells, NSG mice
were used (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ). For transplantation of mouse cells, C57BL/6J mice
were used. For mM1 organoid transplantations, 1  105 cells were prepared from organoid cultures
as a 45 mL suspension of 50% Matrigel in PBS and injected into the pancreas. For p63 knockout
experiments in vivo, KLM1-Cas9 cells were first infected with Lenti-luciferase-blast vector and a sta-
ble KLM1-Cas9-luciferase cell line was generated by selection with 10 mg/ml blasticidin. These cells
were subsequently infected with control or p63 sgRNAs in LRNG vectors as described above. G418-
selected cells were counted by trypan blue exclusion and 5  104 viable cells were prepared as a 50
mL suspension of 50% Matrigel in PBS and injected into the pancreas. For in vivo experiments using
SUIT2-luciferase cells, these cells were infected with LentiV-DNp63-neo vector or the empty vector
as a control and two days post infection, transduced cells were selected 1 mg/ml of G418 for five
days and on day seven post infection, G418-selected cells were counted by trypan blue exclusion
and 2  104 viable cells were prepared as a 50 mL suspension of 50% Matrigel in PBS and injected
into the pancreas. For bioluminescence imaging, mice were intraperitoneally (IP) injected with
D-Luciferin (50 mg/kg) and analyzed using an IVIS Spectrum system (Caliper Life Sciences) ten
minutes post IP injection.
Histology and immunohistochemistry
Histological analysis and p63 immunohistochemistry (IHC) was performed as previously described
(Somerville et al., 2018). Primary antibodies used were p63 (Cell Signaling; 39692). Hematoxylin
and eosin and Masson’s trichrome staining were performed according to standard protocols. Stained
sections were scanned with Aperio ScanScope CS and to quantify p63, the percentage of strong
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positive nuclei was calculated relative to the total number of nuclei with the ImageScope nuclear v9
algorithm.
Immunofluorescence staining
To stain for myeloperoxidase and Ly6G, paraffin sections were deparaffinized and rehydrated, and
antigen retrieval was carried out by boiling slides in Tris EDTA buffer (10 mM Tris Base, 1 mM EDTA,
pH 9.0) for 6 min in a pressure cooker. The slides were blocked with 1x blocking buffer (PBS contain-
ing 2.5% BSA and 5% goat serum) and Fc receptor blocker (Innovex Biosciences, Richmond, CA),
before incubating with anti-myeloperoxidase (1:200, AF3667, R and D) or anti-Ly6G (1:200, #551459,
BD Pharmingen) antibody overnight at 4˚C. After two washes in PBS, slides were incubated in the
presence of fluorochrome-conjugated secondary antibodies (1:250, Invitrogen) for 1 hr, and counter-
stained with DAPI (1:200 dilution; Life Technologies). Images were collected at 40x magnification
using a Leica SP8 confocal and were analyzed using ImageJ software.
Multiplex immunofluorescence staining of human PDA patient tissues
Human tissue samples were collected from end stage PDA patients within 3 hr of the patient passing
at the Rapid Autopsy Pancreatic Program (RAPP) at the University of Nebraska Medical Center. At
autopsy, pathologists identified primary tumor and metastatic sites grossly and samples were col-
lected from tumor, adjacent, and uninvolved tissue. Samples were stored in formalin for rapid paraf-
fin imbedding. 5mm-thick sections were cut and mounted onto charged slides. Immunofluorescent
analysis was then performed as follows. The antibody recognizing MPO (Abcam: ab9535) was
directly conjugated to fluorescent moieties using Cy5 labeling kits obtained from GE Health (Amer-
sham CyDye kits). Alpha-SMA was purchased directly conjugated to Cy3 (Sigma Aldrich: A2547).
Secondary antibodies were used to identify p63 (Cell Signaling: 39692) and Muc1 (Abcam:
ab80952). The slides were then deparaffinized and rehydrated using xylene and an alcohol gradient.
Antigen retrieval was performed using heated acidic citrate buffer for twenty minutes at low heat in
a microwave and the slides were blocked in 1% BSA. The slides were stained with directly labeled
antibodies or primary and secondary antibodies as needed. Coverslips were mounted using mount-
ing media with DAPI and allowed to dry for 24 hr before scanning. Following slide scanning, the
slides were decoverslipped via inversion in agitated PBS. Once the cover slip was removed the slides
were submerged in 3% Triton for ten minutes. Slides were then left in an agitated alkaline H2O2 solu-
tion for fifteen minutes to quench the fluorescent molecule and allow for restaining with a new set of
directly labeled antibodies. Three rounds of staining were performed. Slide scanning was performed
using a Pannoramic 250 whole slide scanner at x20 (3D Histech). Slides were scanned with the test
tissue and a sequential control cut, using consistent exposure for each antibody. Once slides were
scanned, they were analyzed using HALO (Indica Labs), a whole slide image analysis software, to
determine the exposure of each marker across the tumor microenvironment. Calling a positive ‘hit’
was based on the average for visual thresholding across five different samples and then applied to
all tissue with that antibody stain. These data were used to determine the percentage of cells
expressing each marker. A random forest masking algorithm was used to remove autofluorescence
associated with tissue damage. Only the tumor, and not the surrounding adjacent normal or necrotic
tissue, was analyzed.
Flow cytometry and cell sorting
Tumors were processed as previously described (O¨hlund et al., 2017). For sorting of cancer cells,
fibroblasts and immune cells from xenografted tumors, cells were stained for 30 min with anti-mouse
CD45-PerCP-Cy5-5 (103132; BioLegend), PDPN-APC/Cy7 (127418; BioLegend) and anti-human
CD326 (EPCAM)-AlexaFluor 647 (324212; BioLegend), anti-human/mouse E-Cadherin- AlexaFluor
647 (147304; BioLegend) and DAPI for 15 min. Cells were sorted on the FACSAria cell sorter (BD)
for DAPI/CD45 EPCAM/E-Cadherin+ (cancer cells), DAPI/CD45/EPCAM/E-Cadherin PDPN+ (fibro-
blasts) and DAPI-CD45+ (immune cells) cell populations. Sorted cells were pelleted and resuspended
in TRIzol for RNA extraction. For flow cytometric analysis of processed mM1 tumors, antibodies
used for analysis of myeloid cells were: anti-mouse CD45-BV510 (103138; BioLegend), F4/80-BV785
(123141; BioLegend), Ly6G/Ly6C (Gr-1)-PE (108408; BioLegend) and CD11b-PE-Cy7 (101216; BioLe-
gend); antibodies used for analysis of T-cells cells were: anti-mouse CD45-BV510 (103138;
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BioLegend), CD8a-APC-Cy7 (100714; BioLegend), CD4-APC (100516; BioLegend) and TCRb-PE-Cy7
(109222; BioLegend). For flow cytometric analysis of processed xenografted tumors, antibodies used
were anti-mouse CD45-PerCP-Cy5.5 (103132; BioLegend), F4/80-BV785 (123141; BioLegend), Ly6G-
Ly6C (Gr-1)-PE (108408; BioLegend) and CD11b-AlexaFluor 488 (101217; BioLegend). Fixable viabil-
ity dye eFluor450 (eBioscience) was used to differentiate between live and dead cells.
Neutrophil isolation and transwell migration assays
Neutrophil isolation was performed as previously described (Albrengues et al., 2018). Transwell
migration assays were performed with conditioned media derived from cell lines ectopically express-
ing p63 or the empty vector that were cultured alone or in combination with mouse PSCs for five
days in Matrigel. 5  103 SUIT2 cells and 4  104 PSCs were used for the co-cultures. The condi-
tioned media were added to the lower chamber, and primary mouse neutrophils (2.5  105) were
seeded in 0.5% FBS containing DMEM in the upper chamber of a 3 mm FluoroBlok cell culture insert
(08-772-141; Corning) in a 24 well plate. 500 ng of recombinant mouse (250-11; Peprotech) or
human (300-11; Peprotech) CXCL1 was added to DMEM with 5% FBS on the day of seeding neutro-
phils as controls. For experiments with blocking antibodies, 10 mg/ml human CXCL1 (MAB275-100;
R and D Systems) or IgG2B isotype control (MAB004; R and D Systems) was added to the neutro-
phils prior to the addition of the conditioned media. After 24 hr, the FluoroBlok membrane was
stained with DAPI (0.05 mg/ml; D1306; Thermo Fisher Scientific) for 5 min, rinsed in water and
mounted onto glass slides using mounting media (17985–16; Electron Microscopy Sciences). The
number of invading neutrophils was counted in 10 random fields of view using a fluorescence micro-
scope (Leica SP8 Confocal microscope).
RNA-seq library construction
RNA-seq libraries were constructed using the TruSeq sample Prep Kit V2 (Illumina) according to the
manufacturer’s instructions. Briefly, 0.5–2 mg of purified RNA was poly-A selected and fragmented
with fragmentation enzyme. cDNA was synthesized with Super Script II Reverse Transcriptase
(Thermo Fisher; 18064014), followed by end repair, A-tailing and PCR amplification. RNA-seq librar-
ies were single-end sequenced for 50 bp, or for xenograft RNA-seq analysis paired-end sequenced
for 150 bp, using an Illumina NextSeq platform (Cold Spring Harbor Genome Center, Woodbury).
RNA-Seq data analysis
Single end 50 bp sequencing reads were mapped to the mm10 or hg38 genomes using HISAT2 with
standard parameters (Kim et al., 2015). Structural RNA was masked and, unless stated otherwise,
differentially expressed genes were identified using Cuffdiff (Trapnell et al., 2010). All the following
analysis was performed on genes with an RPKM value no less than two in either control or experi-
mental samples. Heat maps of standardized expression values for differentially expressed genes
were generated using Morpheus from the Broad Institute (https://software.broadinstitute.org/mor-
pheus). To generate ranked gene lists for Pre-ranked GSEA, genes were ranked by their mean log2
fold change between the two experimental groups of interest. Gene ontology analysis was per-
formed using Metascape (Zhou et al., 2019). For clustering of mouse PSC cultures, the log2(RPKM
+1) values for each cell line was used to generate a heat map of similarity matrix by Pearson correla-
tion, which was subsequently clustered by Euclidean distance with average linkage using Morpheus.
Group 1 and Group 2 cultures were then analyzed using Cuffdiff and those genes with log2 fold
change >1 and a FDR value <0.05 were considered and differentially expressed. For GSEA using the
Broad Institutes Hallmark gene sets, mouse gene symbols were converted to their orthologous
human symbols and ranked by their average log2 fold change in the respective cultures. For RNA-
seq analysis of flow sorted cancer cells, fibroblasts and immune cells, those genes with a FDR
value <0.05 when comparing sgTP63#4 versus sgNEG tumors were considered and differentially
expressed. For xenograft RNA-seq analysis, paired end 150 bp sequencing reads were mapped to
the mm10 or hg38 genomes using HISAT2 with standard parameters. The alignment sam files were
converted to bam format using the samtools view command. To disambiguate between the human
and mouse reads, Disambiguate (Ahdesma¨ki et al., 2016) was run on the bam files, and the unam-
biguous reads were used for RNA quantification and differential expression analysis using DESeq2
(Love et al., 2014). For human transcripts, those genes with log2 fold change >1 and a FDR
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value <0.1 were considered as differentially expressed. For mouse transcripts, those genes with a
FDR value <0.1 were considered as differentially expressed. To generate a ranked list of mouse
genes for GSEA analysis genes the bottom 30% of expressed genes across all groups were removed.
The iCAF and myCAF gene signatures were defined as the top 200 up- and down-regulated genes
in iCAFs versus myCAFs respectively from the study by O¨hlund et al. (2017). The Squamous-PDA
Identity signature has been previously described (Somerville et al., 2018). RNA-seq datasets follow-
ing p63 expression in SUIT2, PATU8988S, HPAFII, AsPC1 and CFPAC1 cells as well as p63 knockout
or knockdown in BxPC3 and hF3 cells were from a previous study (Somerville et al., 2018).
ChIP-Seq library construction and analysis
ChIP procedures were performed as previously described (Somerville et al., 2018). The antibody
used for ChIP-seq in this study was H3K27ac (ab4729; abcam). ChIP-seq libraries were constructed
using Illumina TruSeq ChIP Sample Prep kit following manufacture’s protocol. Briefly, ChIP DNA was
end repaired, followed by A-tailing and size selection (300–500 bp) by gel electrophoresis using a
2% gel. 15 PCR cycles were used for final library amplification which was analyzed on a Bioanalyzer
using a high sensitivity DNA chip (Agilent). ChIP-seq libraries were single-end sequenced for 50 bp
using an Illumina NextSeq platform (Cold Spring Harbor Genome Center, Woodbury). Single end 50
bp sequencing reads were mapped to the hg19 genome using Bowtie2 with default settings
(Langmead and Salzberg, 2012). After removing duplicated mapped reads using SAMtools 1.4
(Li et al., 2009), MACS 1.4.2 was used to call peaks using input genomic DNA as control
(Feng et al., 2012). Only peaks enriched greater than or equal to 10-fold over input samples were
used for subsequent analyses. Metagene plots were made by centering H3K27ac ChIP-seq regions
on previously defined Squamous Elements (Somerville et al., 2018) extended to ±10,000 bp with
100 bp bins. Super enhancer analysis was performed using Rank Ordering of Super-Enhancers
(ROSE) as described (Love´n et al., 2013; Whyte et al., 2013). p63 ChIP-seq in BxPC3 cells and
H3K27ac ChIP-seq in hN34, hN35, hT85, PATU8988S, AsPC1, HPAFII, SUIT2, hF3 and BxPC3, as
well as H3K27ac in SUIT2 or BxPC3 cells following p63 expression or knockout were from a previous
study (Somerville et al., 2018).
Single cell RNA-Seq analysis
Gene expression matrices along with sample and cluster annotations of 24 PDAC and 11 normal
pancreas samples from the study by Peng et al. (2019) were downloaded from the Chinese National
Genomics Data Center (Genome Sequence Archive accession #CRA001160). Raw digital gene
expression counts from the aggregated samples were used to visualize expression of genes of inter-
est between sample types (Tumor vs Normal) and across annotated clusters. Data processing to gen-
erate an annotated UMAP projection was handled with the Scanpy v1.4.5 software package
(Wolf et al., 2018). Briefly, the 35 gene expression matrices were concatenated, normalized, log-
transformed and filtered of mitochondrial genes and ribosomal genes prior to principal component
analysis, which was restricted to the top 3500 highly variable genes. The top 50 principal compo-
nents were used to compute the KNN graph and 2D UMAP projection using the default settings.
Cells were colored according to cluster assignments from Peng et al. (2019).
Statistics
For graphical representation of data and statistical analysis, GraphPad Prism was used. Statistical
analysis was performed as described in the figure legends.
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